Article info

Original research
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Authors

  1. Correspondence to Professor Mark S Cragg; msc{at}soton.ac.uk; Dr Niranjan Yanamandra; Niranjan.x.yanamandra{at}gsk.com
View Full Text

Citation

Willoughby JE, Dou L, Bhattacharya S, et al
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Publication history

  • Accepted May 16, 2024
  • First published July 4, 2024.
Online issue publication 
July 04, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.